An experimental therapy containing a specific ratio of two naturally occurring pancreatic enzymes may be able to reduce the growth of certain cancers, including…
Gynecological cancer
GYNECOLOGICAL CANCER
Early ovarian cancer trial seeking participants to test higher therapy dose
An early-stage U.S. clinical trial testing the infusion treatment liraltagene autoleucel (lira-cel) for ovarian cancer is now seeking women whose cancer has proven hard…
September is Gynecologic Cancer Awareness Month, and advocacy groups are running campaigns to raise awareness about gynecological cancers, raise funds for research, and…
GYNECOLOGICAL CANCER
New cell model may reveal treatment vulnerabilities in rare cervical cancer
Scientists have developed a new human cell model to study rare cases of cervical cancer that aren’t associated with human papillomavirus (HPV) infection. Few laboratory…
GYNECOLOGICAL CANCER
Study of gynecological cancer therapy moving fast in summer slowdown
A large, late-stage clinical trial testing an immunotherapy in people with gynecological cancers is recruiting participants ahead of schedule, even amid the typically slower…
GYNECOLOGICAL CANCER
Combination therapy completely clears ovarian cancer in lab mice
Combining immunotherapy with an experimental cell therapy from Ernexa Therapeutics completely eliminated ovarian cancer in two-thirds of mice in laboratory experiments. The new data,…
GYNECOLOGICAL CANCER
Targeted drug shrinks hard-to-treat ovarian tumors, early data show
Weekly treatment with Context Therapeutics’ CTIM-76 was generally well tolerated and shrank tumors in some people with heavily pretreated platinum-resistant ovarian cancer, according…
GYNECOLOGICAL CANCER
Cellxlife gains license to ovarian cancer vaccine in clinical trials
Cellxlife signed a licensing agreement for a cell-based vaccine from Mayo Clinic that aims to teach the body’s immune system to recognize and…
GYNECOLOGICAL CANCER
Experimental drug shrinks tumors in hard-to-treat cancers
SIM0505, a treatment being developed by Nextcure and Simcere Zaiming, resulted in partial responses in more than half of patients with hard- to-treat…
GYNECOLOGICAL CANCER
Immunotherapy duo shows promise in tough gynecological cancers
A combination of the immune-modulating treatments Lymphir (denileukin diftitox) and Keytruda (pembrolizumab) led to clinical benefit in nearly half of evaluable patients in an exploratory clinical…
Recent Posts
- My husband and I aren’t just each other’s caregivers; we’re care partners
- Under-the-skin myeloma therapy shows strong responses in Phase 2 trial
- Trial finds treatment eases PV symptoms despite missing main goal
- The quiet courage of taking a short break as a caregiver
- EU clears Tecvayli as solo option when myeloma returns after first treatment